

CHAPTER ONE: INTRODUCTION	1
STUDY GOAL AND OBJECTIVES	1
INTENDED AUDIENCE OF THE STUDY	2
MARKET DEFINITION, SCOPE AND FORMAT	3
INFORMATION SOURCES AND METHODOLOGY.....	4
AUTHOR’S CREDENTIALS	5
RELATED REPORTS FROM BCC RESEARCH	5
BCC ONLINE SERVICES.....	6
DISCLAIMER	6
CHAPTER TWO: SUMMARY	7
SUMMARY.....	7
<i>SUMMARY TABLE GLOBAL DEMAND FOR BIOSIMILARS BY</i>	
<i>VALUE, THROUGH 2016 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL BIOSIMILAR DEMAND BY VALUE</i>	
<i>AND PRODUCT TYPE, 2011 (PERCENT)</i>	9
CHAPTER THREE: MARKET OVERVIEW	10
THE TERMINOLOGY	10
<i>TABLE 1 SIMILAR BIOLOGICAL PRODUCTS: TERMINOLOGIES AND</i>	
<i>THEIR DEFINITIONS AS USED BY VARIOUS REGULATORY</i>	
<i>AGENCIES</i>	11
<i>TABLE 1 (CONTINUED)</i>	12
SMALL MOLECULE GENERICS VERSUS BIOSIMILARS	13
Small Molecule Generics ... (Continued).....	14
DISTINCT INTELLECTUAL PROPERTY ISSUES	15
<i>TABLE 2 BIOSIMILARS VERSUS SMALL MOLECULE GENERICS</i>	16
THE BIOSIMILAR OPPORTUNITY	16
<i>TABLE 3 GLOBAL REVENUES OF LEADING</i>	
<i>BIOPHARMACEUTICALS</i>	17
<i>TABLE 4 BIOLOGIC DRUGS LOSING PATENT PROTECTION</i>	
<i>BETWEEN 2012 AND 2017</i>	18
<i>TABLE 5 POPULAR REFERENCE PRODUCTS TARGETED BY KEY</i>	
<i>PLAYERS</i>	18
VERY EXPENSIVE BIOLOGIC DRUGS DRIVING THE	
DEMAND FOR BIOSIMILARS	18
<i>TABLE 6 ANNUAL COSTS FOR THE TREATMENT USING SOME OF</i>	
<i>THE BIOLOGIC DRUGS</i>	19
<i>TABLE 7 COST COMPARISON FOR RENAL DISEASE-ASSOCIATED</i>	
<i>ANEMIA TREATMENT IN EUROPE</i>	20
WORLDWIDE MARKETS FOR BIOSIMILARS—CURRENT STATUS.....	20
<i>TABLE 8 BIOSIMILARS APPROVED BY EMA, 2011</i>	21
<i>TABLE 9 BIOSIMILARS APPROVED IN OTHER REGULATED</i>	
<i>MARKETS—AUSTRALIA, CANADA, JAPAN, AND THE U.S.</i>	21

<i>TABLE 9 (CONTINUED)</i>	22
<i>TABLE 10 TOP PLAYERS IN THE GLOBAL BIOSIMILAR MARKET</i>	23
MARKET SIZE AND GROWTH TRENDS OF GLOBAL BIOSIMILAR MARKET	23
Market Size and Growth Trends ...(Continued)	24
<i>TABLE 11 THE GLOBAL AND REGIONAL BIOSIMILAR MARKETS BY VALUE THROUGH 2016 (\$ MILLIONS)</i>	25
<i>TABLE 12 THE GLOBAL MARKETS FOR VARIOUS PRODUCT CLASSES OF BIOSIMILARS BY VALUE, THROUGH 2016 (\$ MILLIONS)</i>	26
THE EVOLVING BIOSIMILAR REGULATORY LANDSCAPE	27
UNRESOLVED SCIENTIFIC AND REGULATORY CONCERNS	28
<i>TABLE 13 SCIENTIFIC AND REGULATORY CONCERNS RELATED TO BIOSIMILAR AUTHORIZATION</i>	28
<i>TABLE 13 (CONTINUED)</i>	29
Naming/ Nomenclature	29
Interchangeability	30
Traceability	31
Lack of Access to Reference Product.....	31
CLINICAL CONCERNS	32
<i>TABLE 14 COMMON BIOLOGICS AND THEIR IMMUNOGENICITY POTENTIALS</i>	33
DATA EXCLUSIVITY	34
<i>TABLE 15 DATA EXCLUSIVITY PERIODS OF REFERENCE FOR BIOLOGIC DRUGS IN EU, U.S. AND JAPAN</i>	35
AN OVERVIEW OF THE CURRENT REGULATORY PRACTICES IN U.S., EUROPE, AND SEMI-REGULATED MARKETS	36
EUROPE.....	36
Europe (Continued)	37
THE U.S.....	38
<i>TABLE 16 BIOSIMILAR REGULATION: CURRENT STATUS IN EU AND U.S.</i>	39
<i>TABLE 16 (CONTINUED)</i>	40
<i>TABLE 16 (CONTINUED)</i>	41
OTHER MARKETS.....	41
<i>TABLE 17 BIOSIMILAR GUIDELINES FEATURES ADOPTED BY JAPAN, CANADA AND WHO</i>	42
<i>TABLE 17 (CONTINUED)</i>	43
<i>TABLE 17 (CONTINUED)</i>	44
PARTNERSHIPS, COLLABORATIONS, LICENSING AND ACQUISITIONS DRIVING BIOSIMILAR DEVELOPMENT.....	45
<i>TABLE 18 BIOSIMILAR TARGETED BUSINESS DEALS SIGNED IN 2011</i>	45

<i>TABLE 18 (CONTINUED)</i>	46
<i>TABLE 18 (CONTINUED)</i>	47
BIG PHARMA KEEN TO TAP THE BIOSIMILAR OPPORTUNITY.....	47
<i>TABLE 19 RECENT BIOSIMILAR DEALS MADE BY MULTINATIONAL PHARMACEUTICAL COMPANIES</i>	48
<i>TABLE 19 (CONTINUED)</i>	49
UNUSUAL ENTRANTS FROM ELECTRONIC AND OTHER INDUSTRIES.....	49
KEY CHALLENGES OF THE GLOBAL BIOSIMILAR MARKET	49
<i>TABLE 20 KEY CHALLENGES OF THE GLOBAL BIOSIMILAR MARKET</i>	50
Hesitation of Physicians to Switch to Biosimilars	50
Limitations of CMC Comparability Exercise in Demonstrating Biosimilarity	51
Prohibition to Automatic Substitution by Pharmacists in Key Markets	52
Uncertainty Regarding Extrapolation of Indications Limits Access to Potential Patient Population	52
Low-Price Discounts Ineffective to Shift the Focus From Innovator Brands to Biosimilars	53
Entry of Low Quality Biosimilars Affects the Market Perception.....	53
<i>TABLE 21 KEY CONCERNS OF CHMP REGARDING THE INSULIN BIOSIMILAR APPLICATIONS BY MARVEL LIFE SCIENCES</i>	54
Regulatory Guidelines Regarding Extrapolation of Indications are Vague	55
Long Term Deals Between Big Pharma and Customers May Impact Biosimilar Opportunity	55
Emerging Interest in Biobetters Can Impact the Market Share of Biosimilars.....	55
Data Exclusivity Period of Innovator Biologic Drugs Impact the Profitability of Biosimilars.....	56
High Development and Production Costs Leading to High Prices and Low Savings from Biosimilars.....	56
The Lack of Consensus Between Stakeholders Slows Down the Regulatory Process Development	57
PRICING OF BIOSIMILARS	57
<i>TABLE 22 FACTORS INFLUENCING THE PRICING STRATEGIES FOR BIOSIMILARS</i>	58
The Role of Payers	59
THE RICH BIOSIMILAR PIPELINE	59
<i>TABLE 23 BIOSIMILAR PRODUCTS IN ADVANCED STAGES OF DEVELOPMENT WORLDWIDE</i>	59

<i>TABLE 23 (CONTINUED)</i>	60
CHAPTER FOUR: BIOSIMILAR MARKETS IN EUROPE.....	61
<i>TABLE 24 DETAILS OF BIOSIMILAR APPROVALS IN THE EU</i>	61
<i>TABLE 24 (CONTINUED)</i>	62
LEGISLATION AND POLICIES IN THE EU AND MEMBER STATES	62
<i>TABLE 25 MAIN BIOSIMILAR REGULATORY TEXTS IN EU</i>	63
<i>TABLE 25 (CONTINUED)</i>	64
<i>TABLE 26 BIOSIMILAR GUIDELINES PUBLISHED IN THE EU</i>	65
<i>TABLE 26 (CONTINUED)</i>	66
<i>TABLE 26 (CONTINUED)</i>	67
REFERENCE PRODUCTS AND THEIR MARKET EXCLUSIVITY	
PERIODS IN THE EU	67
<i>TABLE 27 NUMBER OF YEARS OF EFFECTIVE MARKET</i>	
<i>EXCLUSIVITY ENJOYED BY SOME OF THE INNOVATOR BRANDS</i>	
<i>ACROSS EU5</i>	68
THE MARKET AUTHORIZATION PROCESS OF BIOSIMILARS IN	
THE EU.....	68
<i>TABLE 28 SUMMARY OF THE MARKET AUTHORIZATION PROCESS</i>	
<i>OF BIOSIMILARS IN THE EU</i>	69
<i>TABLE 28 (CONTINUED)</i>	70
AVAILABILITY OF BIOSIMILARS IN MEMBER STATES	70
<i>TABLE 29 LAUNCHING DATES OF BIOSIMILAR BRANDS ACROSS</i>	
<i>VARIOUS EU MEMBER STATES</i>	71
THE BIOSIMILAR MARKET IN EU	72
<i>TABLE 30 THE BIOSIMILAR MARKET IN THE EU BY VALUE,</i>	
<i>THROUGH 2016 (\$ MILLIONS)</i>	72
<i>TABLE 31 THE RISING MARKET SHARE OF BIOSIMILARS IN THE</i>	
<i>EU MARKET, 2007-2011</i>	73
<i>TABLE 32 THE MARKET PENETRATION OF SOMATROPIN,</i>	
<i>ERYTHROPOIETIN AND FILGRASTIM BIOSIMILARS ACROSS</i>	
<i>EU5, 2011 (%)</i>	74
<i>TABLE 33 BIOSIMILAR ACCEPTANCE IN SELECTED NON-EU5</i>	
<i>MEMBER STATES (%)</i>	74
THE PUZZLING SLOW MARKET GROWTH OF	
BIOSIMILARS IN EUROPE	74
MOLECULE TYPE AND INDICATIONS WILL PLAY KEY	
ROLES IN THE BIOSIMILAR UPTAKE IN EUROPE.....	75
HEALTH CONCERNS REGARDING INTERCHANGEABILITY – A	
KEY CHALLENGE	75
<i>TABLE 34 POLICIES REGARDING AUTOMATIC SUBSTITUTION OF</i>	
<i>BIOSIMILARS ACROSS THE EU</i>	76
COMPLEXITY ASSOCIATED WITH BIOSIMILAR PRODUCTION IS	
LEADING TO SUPPLY SHORTAGES IN EUROPE	76

ABBREVIATION OF REGULATORY ASSESSMENTS OF BIOSIMILARS	77
THE PRICING AND REIMBURSEMENT (P&R) POLICIES ACROSS THE MEMBER STATES.....	77
<i>TABLE 35 POTENTIAL INFLUENCE OF THE PRICE APPROVAL DELAYS ON LAUNCHING PRIORITIES BY BIOSIMILAR COMPANIES IN SELECTED EU MEMBER STATES.....</i>	<i>78</i>
THE REFERENCE PRICING SYSTEM (RPS)	79
<i>TABLE 36 REFERENCE PRICING SYSTEMS IMPLEMENTED IN EU MEMBER STATES.....</i>	<i>80</i>
RPS versus Health Technology Assessment (HTA)	81
<i>TABLE 37 COMPARISON OF THE POLICIES INFLUENCING THE P&R SCENARIO OF BIOSIMILARS ACROSS EU5</i>	<i>82</i>
<i>TABLE 38 PHARMACEUTICAL P&R POLICIES AND PROCESSES IN SELECTED NON-EU5 MEMBER STATES</i>	<i>83</i>
<i>TABLE 38 (CONTINUED).....</i>	<i>84</i>
<i>TABLE 38 (CONTINUED).....</i>	<i>85</i>
<i>TABLE 38 (CONTINUED).....</i>	<i>86</i>
Biosimilar Price and Market Competition	86
<i>TABLE 39 THE IMPACT OF EPO BIOSIMILAR ENTRY IN GERMANY</i>	<i>86</i>
Uptake of Biosimilars Faster in the Retail Sector	87
GERMANY	87
<i>TABLE 40 DRIVERS OF THE BIOSIMILAR MARKET IN GERMANY</i>	<i>88</i>
STRONG GOVERNMENT SUPPORT	88
High Payer Pressures	88
Fixed Reference Price (FRP) System	88
Pre-Defined Regional Quotas.....	89
<i>TABLE 41 REGIONAL PRESCRIPTION QUOTAS FOR EPO BIOSIMILARS IN GERMANY (%).....</i>	<i>89</i>
Generic Friendly Market.....	89
FAVORABLE APPROACH BY PHYSICIANS	90
REPRESENTATION BY REPUTED COMPANIES.....	90
THE REGULATORY SCENARIO IN GERMANY	90
FRANCE.....	91
REGULATORY STATUS OF BIOSIMILARS AND REIMBURSEMENT PROCESSES IN FRANCE	92
<i>TABLE 42 REGULATORY AUTHORITIES/ORGANIZATIONS INVOLVED IN MARKET AUTHORIZATION OF MEDICINES IN FRANCE.....</i>	<i>92</i>
<i>TABLE 42 (CONTINUED).....</i>	<i>93</i>
The Rising Acceptance of Generic Drugs in France.....	93
The Price Cuts Make Biosimilar Prices Equivalent to Those of the Originators	94

Automatic Substitution by Pharmacists is Banned in the Case of Biosimilars.....	94
HIGH LEVELS OF BRAND LOYALTY AND LOW LEVELS OF ACCEPTABILITY BY PHYSICIANS	94
SPAIN.....	95
THE REGULATORY ENVIRONMENT IN SPAIN.....	95
Before 2010	95
The Royal Decree on the Rationalization of Drug Expenditure and Other Regulatory Measures Introduced in 2010	96
Additional Regulatory Measures Implemented in 2011	96
Low Prices Affect Drug Availability	97
THE ROLE OF AUTONOMOUS REGIONS IN SPAIN	97
SPECIFIC MEASURES TARGETING THE DEMAND FOR BIOSIMILARS	97
ITALY	98
PHARMACEUTICAL REGULATORY STRUCTURE IN ITALY	98
<i>TABLE 43 ORGANIZATIONS AND COMMITTEES INVOLVED IN THE PHARMACEUTICAL REGULATION PROCESSES IN ITALY.....</i>	<i>99</i>
<i>TABLE 43 (CONTINUED).....</i>	<i>100</i>
P&R Procedures in Italy.....	100
<i>TABLE 44 NEGOTIATED PRICE REDUCTIONS FOR BIOSIMILARS COMMERCIALIZED IN ITALY</i>	<i>101</i>
Italian Regulation Does Not Favor Substitutability of Biosimilars.....	101
AVAILABILITY OF BIOSIMILARS IN ITALY.....	101
<i>TABLE 45 BIOSIMILARS AVAILABLE IN ITALY.....</i>	<i>102</i>
THE IMPACT OF THE AUSTERITY MEASURES BY THE GOVERNMENT ON THE BIOSIMILAR MARKET	102
<i>TABLE 46 AUSTERITY MEASURES WITH POTENTIAL IMPACT ON BIOSIMILARS MARKET IN ITALY</i>	<i>103</i>
THE ‘PAY FOR PERFORMANCE’ APPROACH IN ITALY	104
THE UNITED KINGDOM.....	104
PHARMACEUTICAL P&R PROCESSES IN THE U.K.....	104
HEALTH TECHNOLOGY ASSESSMENT (HTA) IN THE U.K.	104
Health Technology Assessment ... (Continued)	105
<i>TABLE 47 AUTHORITIES OF PHARMACEUTICAL REGULATION AND P&R PROCESSES IN THE U.K.....</i>	<i>106</i>
MARKET PENETRATION OF BIOSIMILARS IN THE U.K.....	107
<i>FIGURE 1 DEMAND TRENDS OF FILGRASTIM IN THE U.K. AFTER THE LAUNCH OF BIOSIMILARS, NOVEMBER. 2008-JUNE 2011 (BY VOLUME PERCENT)</i>	<i>108</i>
REST OF THE EU	108

<i>TABLE 48 LAUNCHING DATES OF SELECTED EPO AND FILGRASTIM BIOSIMILARS IN AUSTRIA, GERMANY, SWEDEN AND THE NETHERLANDS</i>	109
DENMARK	109
Regulation and Reimbursement	109
Market Penetration of Biosimilars	110
GREECE	110
HUNGARY	111
POLAND	112
SWEDEN	112
THE NETHERLANDS	113
 CHAPTER FIVE: BIOSIMILAR MARKETS IN THE U.S.	114
BIOSIMILAR REGULATION STATUS IN THE U.S.	114
BIOSIMILAR REGULATION STATUS ... (CONTINUED)	115
<i>TABLE 49 KEY LEGISLATIONS SHAPING THE REGULATORY FRAMEWORK OF THE EVOLVING BIOSIMILARS MARKET IN THE U.S.</i>	116
<i>TABLE 49 (CONTINUED)</i>	117
<i>TABLE 50 DIFFERENCES BETWEEN HATCH-WAXMAN PATENT ENFORCEMENT AND THE BPCIA PATENT FRAMEWORK</i>	117
<i>TABLE 50 (CONTINUED)</i>	118
THE EXISTING REGULATORY PATHWAYS FOR THE APPROVAL OF DRUGS AND BIOLOGICS IN THE U.S.	118
<i>TABLE 51 REGULATORY PATHWAYS FOR THE APPROVAL OF SMALL MOLECULE DRUGS AND BIOLOGIC DRUGS</i>	119
FFDCA and the Approval of Simple Biosimilars	119
Similar Biologic Drugs Marketed in the U.S.....	119
<i>TABLE 52 SIMILAR RECOMBINANT BIOLOGIC PRODUCTS APPROVED BY THE FDA</i>	120
The Evolving Biosimilar Regulatory Approval Pathway Based on PPACA and BPCIA	120
<i>TABLE 53 THE EVOLVING BIOSIMILAR PATH TO APPROVAL IN THE U.S.</i>	121
<i>TABLE 53 (CONTINUED)</i>	122
<i>TABLE 53 (CONTINUED)</i>	123
“Umbrella Exclusivity” and “Evergreening”: The Tussle over the Exclusivity Provision in BPCIA	124
The Status of the PHS 351 User Fee Proposal by FDA.....	125
<i>TABLE 54 THE PROPOSED USER FEE PROGRAM FOR BIOSIMILARS BY THE FDA FOR FISCAL YEARS 2013-2017</i>	126
<i>TABLE 55 PERFORMANCE GOALS PROPOSED FOR THE FDA FOR APPLICATION REVIEWS</i>	127
<i>TABLE 56 PERFORMANCE GOALS PROPOSED FOR FDA FOR MEETINGS WITH THE BIOSIMILAR APPLICANT</i>	128

“Totality of the Evidence” Likely to be the Approach by FDA.....	128
Interactions between EMA and FDA on Biosimilar Regulations.....	129
COMPARISON OF THE EVOLVING FDA REGULATION WITH THE BIOSIMILAR REGULATIONS ESTABLISHED BY EMA.....	129
<i>TABLE 57 COMPARISON OF BIOSIMILAR REGULATORY APPROACHES OF EMA AND FDA</i>	130
<i>TABLE 57 (CONTINUED)</i>	131
<i>TABLE 57 (CONTINUED)</i>	132
<i>TABLE 57 (CONTINUED)</i>	133
<i>TABLE 57 (CONTINUED)</i>	134
PAYER ACCEPTANCE TRENDS OF BIOSIMILARS IN THE U.S.	134
COMPANIES OPTING FOR STANDARD BLAS INSTEAD OF GOING THE BIOSIMILAR ROUTE.....	135
THE BIOSIMILAR MARKET IN THE U.S.	136
<i>TABLE 58 THE BIOSIMILAR MARKET SIZE IN THE U.S., THROUGH 2016 (\$ MILLIONS)</i>	136
CHAPTER SIX: BIOSIMILAR MARKETS IN THE ASIA-PACIFIC REGION.....	137
BIOSIMILAR MARKETS IN THE ASIA-PACIFIC REGION	137
THE BIOSIMILAR MARKET SIZE IN ASIA-PACIFIC	138
<i>TABLE 59 THE BIOSIMILAR MARKETS IN APAC, BY PRODUCT CLASSES THROUGH 2016 (\$ MILLIONS)</i>	138
<i>TABLE 60 THE BIOSIMILAR MARKETS IN APAC BY COUNTRY, THROUGH 2016 (BY VALUE, \$ MILLIONS)</i>	138
JAPAN.....	139
<i>TABLE 61 DRIVERS AND RESTRAINTS OF THE BIOSIMILAR MARKET IN JAPAN</i>	140
AN OVERVIEW OF BIOSIMILAR REGULATIONS IN JAPAN	140
<i>TABLE 62 IMPORTANT POINTS OF THE BIOSIMILAR REGULATION IN JAPAN</i>	141
<i>TABLE 62 (CONTINUED)</i>	142
THE BIOSIMILAR MARKET IN JAPAN.....	142
<i>FIGURE 2 THE JAPANESE BIOSIMILAR MARKET (\$ MILLIONS)</i>	143
ELECTRONIC COMPANIES ENTERING THE BIOSIMILAR SECTOR WITH SIGNIFICANT INVESTMENTS	144
RISING COLLABORATIONS AND ACQUISITIONS TARGETING THE BIOSIMILAR SECTOR IN JAPAN	144
<i>TABLE 63 RECENT ACQUISITIONS AND PARTNERSHIPS IN JAPAN IN THE BIOSIMILAR SECTOR</i>	144
<i>TABLE 63 (CONTINUED)</i>	145
SOUTH KOREA.....	145

BIOVISION 2016	146
REGIONAL BIOCLUSTERS	147
<i>TABLE 64 REGIONAL BIOCLUSTERS IN SOUTH KOREA</i>	147
GOVERNMENT POLICIES TO ATTRACT INVESTMENTS IN THE BIOTECHNOLOGY SECTOR.....	147
BIOSIMILAR REGULATORY STATUS IN KOREA	148
<i>TABLE 65 HIGHLIGHTS OF THE BIOSIMILAR REGULATION IN KOREA</i>	149
<i>TABLE 65 (CONTINUED)</i>	150
BUILDING BIOSIMILAR RESEARCH CAPACITY.....	150
<i>TABLE 66 RELEVANT AUTHORITIES AND INDUSTRY ASSOCIATIONS IN KOREA</i>	151
THE BIOSIMILAR SPECIAL PROGRAM ACCELERATING INVESTMENTS IN THE FIELD.....	151
<i>TABLE 67 LIST OF RECENT INVESTMENTS IN THE BIOSIMILAR SECTOR IN KOREA</i>	152
KEY PLAYERS IN THE MARKET	153
<i>TABLE 68 KEY KOREAN PLAYERS IN THE BIOSIMILAR MARKET WITH COMMERCIALIZED PRODUCTS</i>	153
<i>TABLE 69 KOREAN COMPANIES WITH BIOSIMILAR PRODUCTS IN ADVANCED STAGES OF DEVELOPMENT</i>	154
<i>TABLE 69 (CONTINUED)</i>	155
<i>TABLE 70 BIOSIMILARS OF MONOCLONAL ANTIBODY BLOCKBUSTERS UNDER DEVELOPMENT IN KOREA</i>	155
BIOSIMILAR MARKET IN KOREA.....	156
<i>FIGURE 3 THE KOREAN BIOSIMILAR MARKET BY VALUE 2010- 2016 (\$ MILLIONS)</i>	156
<i>FIGURE 3 (CONTINUED)</i>	157
CHINA.....	157
CHARACTERISTICS AND TRENDS OF THE CHINESE BIOPHARMACEUTICAL INDUSTRY.....	157
<i>TABLE 71 CHINESE BIOSIMILAR MARKET: KEY CHARACTERISTICS</i>	158
<i>TABLE 71 (CONTINUED)</i>	159
Increasing Disease Burden Driving the Market	159
Unmet Medical Needs	160
Lack of Expertise in the Production of Highly Demanding Products such as Monoclonal Antibodies	160
<i>TABLE 72 MAB PRODUCTS LAUNCHED IN CHINA BY DOMESTIC COMPANIES</i>	161
Lack of Expertise in...(Continued).....	162
<i>TABLE 73 KEY MAB MANUFACTURERS AND THEIR PRODUCTION CAPACITIES IN CHINA</i>	163
Biopharmaceutical Affordability for Chinese Patients.....	163

CURRENT REGULATORY LANDSCAPE OF BIOSIMILARS IN CHINA	163
Current Regulatory Landscape ...(Continued).....	164
FINANCIAL ENVIRONMENT OF BIOSIMILAR INDUSTRY IN CHINA	165
<i>TABLE 74 VENTURE CAPITAL FIRMS WITH HEALTHCARE/BIOTECHNOLOGY COMPANIES IN THEIR PORTFOLIO IN CHINA.....</i>	<i>166</i>
<i>TABLE 75 GOVERNMENT PROGRAMS TARGETING PROMOTION OF INNOVATION IN SCIENCE AND TECHNOLOGY (S&T) IN CHINA.....</i>	<i>167</i>
<i>TABLE 75 (CONTINUED).....</i>	<i>168</i>
<i>TABLE 75 (CONTINUED).....</i>	<i>169</i>
ADOPTION OF HYBRID BUSINESS MODELS	170
Biotech Parks in China	170
Key Players in the Market	170
<i>TABLE 76 BIOSIMILAR COMPANIES AND THEIR PRODUCTS IN CHINA.....</i>	<i>170</i>
<i>TABLE 76 (CONTINUED).....</i>	<i>171</i>
THE BIOSIMILAR MARKET IN CHINA.....	171
<i>FIGURE 4 THE CHINESE BIOSIMILAR MARKET BY VALUE, 2010- 2016 (\$ MILLIONS).....</i>	<i>172</i>
<i>FIGURE 4 (CONTINUED)</i>	<i>173</i>
INDIA	173
<i>TABLE 77 DRIVERS OF INDIAN BIOSIMILAR MARKET.....</i>	<i>174</i>
RISING INVESTMENTS IN INDIAN BIOSIMILAR SECTOR	175
<i>TABLE 78 BIOSIMILAR-RELATED INVESTMENTS AND BUSINESS DEALS BY INDIAN COMPANIES.....</i>	<i>175</i>
<i>TABLE 78 (CONTINUED).....</i>	<i>176</i>
GOVERNMENT INITIATIVES.....	176
Government Initiatives (Continued).....	177
<i>TABLE 79 THE BIOTECH PARKS IN INDIA.....</i>	<i>178</i>
<i>TABLE 79 (CONTINUED).....</i>	<i>179</i>
<i>TABLE 79 (CONTINUED).....</i>	<i>180</i>
THE REGULATORY LANDSCAPE OF BIOSIMILAR INDUSTRY IN INDIA	180
<i>TABLE 80 IMPORTANT REGULATIONS INFLUENCING BIOSIMILAR INDUSTRY GROWTH IN INDIA.....</i>	<i>181</i>
<i>TABLE 80 (CONTINUED).....</i>	<i>182</i>
<i>TABLE 81 AUTHORITIES IN INDIA RELATED TO BIOSIMILAR INDUSTRY REGULATIONS AND THEIR RESPONSIBILITIES</i>	<i>182</i>
<i>TABLE 81 (CONTINUED).....</i>	<i>183</i>
REGISTRATION PROCESS OF A BIOSIMILAR DRUG IN INDIA	183

THE FINANCIAL ENVIRONMENT OF BIOSIMILAR INDUSTRY IN INDIA.....	184
THE TECHNOLOGICAL CAPABILITIES OF INDIA IN THE BIOSIMILAR FIELD.....	185
<i>TABLE 82 TECHNOLOGICAL CHALLENGES OF BIOSIMILAR COMPANIES IN INDIA.....</i>	<i>186</i>
THE BIOSIMILAR MARKET IN INDIA.....	187
<i>TABLE 83 KEY PLAYERS AND THEIR PRODUCTS IN THE INDIAN BIOSIMILAR MARKET.....</i>	<i>187</i>
<i>TABLE 83 (CONTINUED).....</i>	<i>188</i>
<i>FIGURE 5 THE INDIAN BIOSIMILAR MARKET BY VALUE, 2010-2016 (\$ MILLIONS).....</i>	<i>188</i>
REST OF APAC.....	189
AUSTRALIA.....	189
SINGAPORE.....	190
TAIWAN.....	191
<i>TABLE 84 BIOTECHNOLOGY FOCUSED SCIENCE PARKS IN TAIWAN.....</i>	<i>192</i>
Taiwan (Continued).....	193
THE BIOSIMILAR MARKET IN REST OF APAC.....	194
<i>FIGURE 6 THE BIOSIMILAR MARKET FOR THE REST OF APAC, THROUGH 2016 (\$ MILLIONS).....</i>	<i>194</i>
CHAPTER SEVEN REST OF THE WORLD (ROW) MARKETS.....	195
REST OF THE WORLD (ROW) MARKETS.....	195
<i>TABLE 85 THE MARKET SIZE OF BIOSIMILARS IN ROW BY VALUE, THROUGH 2016 (\$ MILLIONS).....</i>	<i>196</i>
CANADA.....	196
CUBA.....	197
Cuba (Continued).....	198
BRAZIL.....	199
<i>TABLE 86 AGENCIES/ OFFICES INVOLVED IN PHARMACEUTICAL REGULATION IN BRAZIL.....</i>	<i>200</i>
<i>TABLE 86 (CONTINUED).....</i>	<i>201</i>
<i>TABLE 87 KEY REGULATIONS SHAPING THE PHARMACEUTICAL INDUSTRY IN BRAZIL.....</i>	<i>202</i>
MEXICO.....	203
ISRAEL.....	204
RUSSIA.....	205
Russia (Continued).....	206
CHAPTER EIGHT: TECHNOLOGY TRENDS.....	207
TRENDS IN BIOSIMILAR MANUFACTURING PROCESSES.....	207
NEW TRENDS IN CELL LINE DEVELOPMENT.....	207

<i>TABLE 88 EMERGING TECHNOLOGY PLATFORMS FOR BIOSIMILAR CELL LINE DEVELOPMENT</i>	208
<i>TABLE 88 (CONTINUED)</i>	209
ALTERNATE HOST SYSTEMS.....	209
SCAFFOLD/MATRIX ATTACHMENT REGIONS (S/MARS)	210
UBIQUITOUS CHROMATIN OPENING ELEMENTS (UCOE).....	210
ZINC FINGER MEDIATED HOST CELL ENGINEERING.....	210
TRANSIENT GENE EXPRESSION (TGE)	211
REGULATORY RNA ENGINEERING	211
SINGLE-USE SYSTEMS AND WAREHOUSE MANUFACTURING	211
EMERGING TRENDS IN ANALYTICAL TECHNOLOGIES.....	212
<i>TABLE 89 CHALLENGES OF ANALYTICAL CHARACTERIZATION OF BIOSIMILAR PRODUCTS</i>	213
<i>TABLE 90 ANALYTICAL METHODS RECOGNIZED BY REGULATORY BODIES FOR COMPARABILITY EXERCISE AND RISK MITIGATION</i>	214
<i>TABLE 90 (CONTINUED)</i>	215
POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE) AND WESTERN BLOTTING	215
ISOELECTRIC FOCUSING (IEF)/PROTEIN BLOTTING.....	215
CAPILLARY ZONE ELECTROPHORESIS (CZE)	216
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC).....	216
SPECTROSCOPIC TECHNIQUES.....	216
MASS SPECTROMETRY (MS)	217
<i>IN VITRO</i> ASSAYS	217
EPITOPE MAPPING	218
DIFFERENTIAL SCANNING CALORIMETRY (DSC)	218
CHAPTER NINE: PATENT ANALYSIS	219
PATENT ANALYSIS	219
<i>TABLE 91 U.S. PATENTS OF MOMENTA PHARMACEUTICALS ON ANALYTICAL METHODS FOR LMWH CHARACTERIZATION</i>	220
<i>TABLE 92 INTERNATIONAL PATENTS ON BIOSIMILAR PRODUCTS BY SELECTED INDUSTRY PLAYERS</i>	221
<i>TABLE 92 (CONTINUED)</i>	222
CHAPTER TEN: COMPANY PROFILES	223
3SBIO INC.	223
<i>TABLE 93 BIOSIMILAR PRODUCTS MARKETED BY 3SBIO</i>	224
AMOYTOP BIOTECH CO., LTD	225
ANHUI ANKE BIOTECHNOLOGY(GROUP) CO., LTD.....	225
APOTEX INC.	226
AVESTHAGEN LIMITED.....	226

BEIJING FOUR RINGS BIOPHARMACEUTICAL CO., LTD.	227
BEIJING SL PHARMACEUTICAL CO., LTD.	228
BHARAT SERUMS AND VACCINES LTD	228
BIOCON LTD.....	229
<i>TABLE 94 SOME OF THE RECENT PARTNERSHIP, ACQUISITION, AND DIVESTMENT DEALS BY BIOCON.....</i>	<i>230</i>
BIOXPRESS THERAPEUTICS SA.....	231
<i>TABLE 95 PIPELINE BIOSIMILAR MABS OF BIOXPRESS THERAPEUTICS SA.....</i>	<i>231</i>
<i>TABLE 95 (CONTINUED).....</i>	<i>232</i>
BIOTON S. A.....	232
<i>TABLE 96 BIOTON GROUP COMPANIES WORLDWIDE.....</i>	<i>233</i>
BLAU FARMACÊUTICA S/A.....	234
BOEHRINGER INGELHEIM	234
CELLTRION GROUP	235
<i>TABLE 97 MARKETING AND CRO PARTNERS OF CELLTRION IN VARIOUS COUNTRIES.....</i>	<i>235</i>
<i>TABLE 97 (CONTINUED).....</i>	<i>236</i>
<i>TABLE 98 BIOSIMILAR PIPELINE OF CELLTRION.....</i>	<i>237</i>
CHINA NATIONAL BIOTECH CORPORATION (CNBC).....	238
CIPLA LIMITED.....	238
CINNAGEN.....	239
CJSC BIOCAD	239
<i>TABLE 99 BIOPHARMACEUTICALS DEVELOPED AND MARKETED BY BIOCAD.....</i>	<i>240</i>
CURAXYS	240
DONG-A PHARMACEUTICAL CO., LTD.....	241
<i>TABLE 100 BIOSIMILAR PRODUCTS OF DONG-A PHARMACEUTICALS</i>	<i>242</i>
DR. REDDY'S LABORATORIES LTD.....	242
DR. REDDY'S LABORATORIES LTD. (CONTINUED)	243
<i>TABLE 101 BIOSIMILAR PRODUCTS MARKETED BY DR. REDDY'S LABORATORIES.....</i>	<i>244</i>
EMCURE PHARMACEUTICALS LTD.	244
FERON LTD.....	245
FINOX BIOTECH	245
FUJIFILM CORPORATION	246
GEDEON RICHTER PLC.....	247
GENESCENCE PHARMACEUTICALS CO., LTD. (GENSCI).....	247
GENEXINE CO. LTD	248
G. H. GENHELIX S.A.....	248
GREEN CROSS LIFE SCIENCE CORPORATION	249
HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD.....	250
HANALL PHARMACEUTICAL CO., LTD.....	250

HANWHA CHEMICAL CORPORATION.....	251
HOSPIRA, INC.	251
<i>TABLE 102 BIOSIMILAR-RELATED INVESTMENTS BY HOSPIRA</i>	<i>252</i>
<i>TABLE 102 (CONTINUED).....</i>	<i>253</i>
<i>TABLE 103 BIOSIMILAR PIPELINE OF HOSPIRA.....</i>	<i>253</i>
<i>TABLE 103 (CONTINUED).....</i>	<i>254</i>
INTAS BIOPHARMACEUTICALS LTD.	254
<i>TABLE 104 IBPL'S BIOSIMILAR PRODUCTS IN THE MARKET.....</i>	<i>255</i>
<i>TABLE 105 MARKETING PARTNERSHIPS ESTABLISHED BY INTAS</i>	
<i>IN VARIOUS MARKETS</i>	<i>256</i>
JCR PHARMACEUTICALS CO., LTD.	256
<i>TABLE 106 RECOMBINANT BIOSIMILAR PIPELINE OF JCR</i>	
<i>PHARMACEUTICALS</i>	<i>257</i>
KISSEI PHARMACEUTICALS CO., LTD.....	257
LG LIFE SCIENCES	258
<i>TABLE 107 BIOLOGIC DRUGS DEVELOPED AND MARKETED BY</i>	
<i>LGLS.....</i>	<i>258</i>
MEDICE ARZNEIMITTEL PUTTER GMBH AND CO. KG	259
MERCK BIOVENTURES.....	259
MJ BIOPHARMA PVT. LTD.....	260
MOMENTA PHARMACEUTICALS	261
MYCENAX BIOTECH INC.....	261
NANOGEN BIOPHARMA.....	262
NCPC GENETECH BIOTECHNOLOGY CO., LTD.	262
NEUCLONE PTY. LIMITED	263
NIPPON KAYAKU CO., LTD.....	264
<i>TABLE 108 BIOSIMILAR PRODUCTS UNDER DEVELOPMENT BY</i>	
<i>NIPPON KAYAKU, JAPAN</i>	<i>264</i>
<i>PHARMAPARK LLC</i>	<i>264</i>
<i>PLANTFORM CORPORATION.....</i>	<i>265</i>
<i>PROBIOMED S.A. DE C.V.....</i>	<i>265</i>
<i>RANBAXY LABORATORIES LTD.</i>	<i>266</i>
<i>RANBAXY LABORATORIES LTD. (CONTINUED).....</i>	<i>267</i>
<i>RELIANCE LIFE SCIENCES PVT LTD</i>	<i>268</i>
<i>TABLE 109 BIOSIMILARS DEVELOPED AND MARKETED BY</i>	
<i>RELIANCE LIFE SCIENCES.....</i>	<i>269</i>
<i>SAMSUNG BIOLOGICS</i>	<i>269</i>
<i>TABLE 110 PARTNERING COMPANIES INVOLVED IN THE</i>	
<i>ESTABLISHMENT OF SAMSUNG BIOLOGICS.....</i>	<i>270</i>
<i>SANDOZ INTERNATIONAL GMBH</i>	<i>270</i>
<i>SCINOPHARM TAIWAN, LTD.....</i>	<i>271</i>
<i>SHANDONG GENELEUK BIOPHARMACEUTICAL CO., LTD.</i>	<i>272</i>
<i>SHANDONG KEXING BIOPRODUCTS CO., LTD.</i>	<i>273</i>
<i>SHANGHAI CELGEN BIOPHARMACEUTICAL CO, LTD.</i>	<i>273</i>

SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD.....	274
SHANGHAI HUAXIN HIGH BIOTECHNOLOGY INC.....	275
SHANGHAI UNITED CELL BIOTECHNOLOGY CO., LTD.....	275
SHANGHAI WANXING BIO-PHARMACEUTICAL CO. LTD	276
SHANTHA BIOTECHNICS	276
SHENZHEN HEPALINK PHARMACEUTICAL CO., LTD.	277
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE CO., LTD.....	278
SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD.....	278
SHENZHEN XINPENG BIO-TECH CO., LTD	279
SICOR BIOTECH UAB	279
SOTEX PHARMACEUTICAL FIRM ZAO.....	280
STADA-ARZNEIMITTEL AG (STADA)	280
TEVA PHARMACEUTICAL INDUSTRIES LTD.	281
<i>TABLE 111 MARKETED AND PIPELINE BIOSIMILAR PRODUCTS OF TEVA PHARMACEUTICALS.....</i>	<i>282</i>
<i>TABLE 112 PARTNERING DEALS/ACQUISITIONS BY TEVA TARGETING THE DEVELOPMENT OF BIOPHARMACEUTICAL PIPELINE</i>	<i>282</i>
<i>TABLE 112 (CONTINUED).....</i>	<i>283</i>
TIANJIN HUALIDA BIOTECHNOLOGY CO., LTD.....	283
USV LIMITED	284
WOCKHARDT LTD.....	284
<i>TABLE 113 BIOSIMILAR PRODUCTS MARKETED BY WOCKHARDT</i>	<i>285</i>
WATSON PHARMACEUTICALS, INC.....	286
ZHONGSHAN HYGENE BIOPHARM CO., LTD.	286
APPENDIX.....	287
<i>TABLE 114 GLOSSARY.....</i>	<i>287</i>
<i>TABLE 114 (CONTINUED).....</i>	<i>288</i>
<i>TABLE 114 (CONTINUED).....</i>	<i>289</i>